OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) continues to hold its recent gains on the chart following the stock’s massive gains so far in 2017. In fact, the stock is beating the Nasdaq Biotechnology Index year-to-date by over 160%. One big part of that strength and resilience (and potential coming follow-on strength) is the performance in the marketplace of the company’s licensed drug sales. Specifically, OBMP management just announced that sales of Bekunis for constipation and Cirkused for stress have so far exceeded projections during the first six months on the market in Mexico.
As you may recall, the two drugs were picked up as a diversification strategy over recent months to equip the company with more heterogenous financing of future growth strategies. According to the company’s recent release, sales from September 16, 2016 to February 16, 2017 were approximately US$330,000, exceeding projections for US$125,000 initially forecast for the first six months at product launch during the third quarter last year. The Company noted in that release that it anticipates that sales efforts will continue to accelerate and anticipates combined sales in the range of US$750,000 to US$850,000 for the products in 2017.
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer.
The company also has a portfolio of targeted therapies. OncBioMune Pharmaceuticals, Inc. is headquartered in Baton Rouge, Louisiana.
As we have previously noted, OBMP is an easy fit for a few different names as far as a take-out candidate. Just starting with those in the space who have shown a clear interest in development or acquisition of assets that offer potential for market share in the prostate cancer segment, one can easily point to the likes of Seattle Genetics, Inc. (NASDAQ:SGEN), Inovio Pharmaceuticals (NASDAQ:INO), Nymox Pharmaceutical Corporation (NASDAQ:NYMX).
Firing on All Cylinders.
As we have recently covered, OBMP management has made several moves in recent weeks to diversify the outcome distribution of its investment portfolio by adding proven, revenue-generating products to its stable of assets.
The company first announced the acquisition of Vitel Laboratorios, S.A. de C.V, which is expected to “transform OncBioMune into a revenue-generating international pharmaceutical company with a more diverse product line with a particularly deep reach throughout Mexico, Central and Latin America, and relationships across Europe and Asia.” The acquisition of Vitel includes two drugs it licenses and sells in Mexico, Bekunis for constipation and Cirkused for stress.
“We are very excited by the initial sales of Bekunis and Cirkused and the fact that they handily exceeded our expectations subsequent to launch, an often challenging time to capture market,” commented Manuel Cosme Odabachian, OncBioMune’s General Manager of Global Operations. “I believe that if we can achieve our goal of commercializing Aagaard® Propolis early in the third quarter that we have an opportunity to exceed US$1.0 million in total sales this year while maintaining strong margins. I am confident that we are going to become a leading pharma throughout Central and South America with our aggressive marketing and licensing strategy that will backstop our clinical work with ProscaVax in Mexico and the United States.”
To see these drugs now outperforming expectations is a great sign. It suggests the company will be able to move more confidently with its core pipeline, and its focus on the ProscaVax pipeline asset, which continues to move toward a huge Phase II trial. That narrative is expected to fuel the this company as it grants OBMP shareholders access to the $7.1 billion prostate cancer treatment space.
Technically, OBMP has massively outperformed the biotech space so far this year, but it isn’t overbought or stretched at present, having worked its way through six weeks of a lateral consolidation that has taken its primary oscillation indicators such as RSI and MACD back down closer to oversold than overbought. That’s chartist language for: this stock no longer looks like it’s gone too far too fast for comfort.
As such, with revenues now set to come in faster than expected, the pipeline moving toward a new and more advanced phase, and the chart no longer stretched, this may be as good a time as ever to take a close look at the stock.
